Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Chemo for Neoadjuvant HNSCC
NCT04922450Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Hunan Cancer Hospital. Primary endpoints: Clinical Remission Rate and Pathological Remission Rate. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04922450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922450.